Literature DB >> 2897548

Antibody-dependent enhancement of HIV infection.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2897548

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  22 in total

1.  Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.

Authors:  P R Johnson; D C Montefiori; S Goldstein; T E Hamm; J Zhou; S Kitov; N L Haigwood; L Misher; W T London; J L Gerin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes.

Authors:  R Anderson; S Wang; C Osiowy; A C Issekutz
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

3.  Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.

Authors:  J Homsy; M Meyer; J A Levy
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

4.  Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses.

Authors:  M Tamura; R G Webster; F A Ennis
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

5.  Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line.

Authors:  G S Gras; D Dormont
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Authors:  P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 7.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

8.  V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.

Authors:  S C Kliks; T Shioda; N L Haigwood; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

9.  Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons.

Authors:  R A June; A L Landay; K Stefanik; T F Lint; G T Spear
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

10.  Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120.

Authors:  A Takeda; J E Robinson; D D Ho; C Debouck; N L Haigwood; F A Ennis
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.